Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure

[1] Drucker DJ(2006)The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696-1705

[2] Nauck MA(2005)Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism Regul Pept 125 173-177

[3] Nystrom T(2004)Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab. 287 E1209-E1215

[4] Gonon AT(2012)Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 1491-1499

[5] Sjoholm A(2004)Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 962-965

[6] Pernow J(2006)Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Cardiac Fail 12 694-699

[7] Nystrom T(2012)Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism Diabetes 61 888-896

[8] Gutniak MK(2014)Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production Cardiovasc Diabetol 13 69-139

[9] Zhang Q(2015)Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes Diabetes Care 38 132-1135

[10] Zhang F(2003)Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats J Hypertens 21 1125-575

[1] Drucker DJ(2006)The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696-1705

[2] Nauck MA(2005)Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism Regul Pept 125 173-177

[3] Nystrom T(2004)Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab. 287 E1209-E1215

[4] Gonon AT(2012)Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 1491-1499

[5] Sjoholm A(2004)Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 962-965

[6] Pernow J(2006)Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Cardiac Fail 12 694-699

[7] Nystrom T(2012)Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism Diabetes 61 888-896

[8] Gutniak MK(2014)Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production Cardiovasc Diabetol 13 69-139

[9] Zhang Q(2015)Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes Diabetes Care 38 132-1135

[10] Zhang F(2003)Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats J Hypertens 21 1125-575